AutoIVF Completes Syndicated Investment Round

AutoIVF Inc. has closed an equity investment round led by Vitrolife Group, with participation from new supporters—Alpha Edison and IVF industry stalwarts. The company did not disclose details of the funding. 

‘’This investment and partnership mark another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care,” Vitrolife Group CEO Bronwyn Brophy O’Connor stated. In conjunction with the funding round, Vitrolife Group Senior Vice President/General Manager-North America Erin Schardt is joining AutoIVF’s Board of Directors.

AutoIVF’s flagship product, OvaReady, is an automated system that simplifies and enhances egg retrieval and preparation in the current in-vitro fertilization (IVF) process and supports decentralizing the egg retrieval process outside traditional IVF laboratory settings.

World Health Organization (WHO) data shows that one in six people globally will experience infertility at some point in their lives. This statistic underscores the need for accessible, high-quality fertility care worldwide.

Led by CEO Ravi Kapur Ph.D., AutoIVF’s founding and leadership team brings more than 200 years of combined experience in IVF, microfluidics, and reproductive health, driving its mission to democratize fertility care, expand global access, and reimagine the future of assisted reproductive technologies.

“The National Institutes of Health’s ongoing support through their Small Business Innovation Research Awards has validated the strength of our technology and our rigorous clinical approach. This foundation has enabled us to demonstrate the real-world impact of OvaReady. With this new investment and partnership, we’re excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem,” Dr. Kapur said.

AutoIVF aims to improve the accessibility, affordability, and efficiency of IVF. The Natick, Mass.-based company has raised more than $16 million in public and private funding, including major National Institute of Health SBIR awards.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Its mission is to be a global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, the firm’s products and services are available in more than 125 countries through a direct presence and distribution network. Vitrolife AB is listed on Nasdaq Stockholm.